CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Retained Earnings	FlexBiosys, Inc.	FlexBiosys, Inc. Common Stock	FlexBiosys, Inc. Additional Paid-In Capital
Balance at Dec. 31, 2021	$ 1,750,067	$ 553	$ 1,572,340	$ (16,886)	$ 194,060
Beginning Balance (in shares) at Dec. 31, 2021		55,321,457
Net income	96,825				96,825
Issuance of common stock for debt conversion	(5)		(5)
Issuance of common stock for debt conversion (in shares)		12
Exercise of stock options and vesting of stock units	463	$ 3	460
Exercise of stock options and vesting of stock units (in shares)		222,727
Tax withholding on vesting of restricted stock units	(14,759)	$ (1)	(14,758)
Tax withholding on vesting of restricted stock units (in shares)		(78,278)
Stock-based compensation expense	14,900		14,900
Translation adjustment	(20,205)			(20,205)
Other	(105)		(105)
Balance at Jun. 30, 2022	1,805,364	$ 555	1,533,762	(37,091)	308,138
Balance (Accounting Standards Update 2020-06 [Member]) at Jun. 30, 2022	(21,817)		(39,070)		17,253
Ending Balance, (in shares) at Jun. 30, 2022		55,465,918
Balance at Mar. 31, 2022	1,766,401	$ 554	1,529,144	(21,574)	258,277
Beginning Balance (in shares) at Mar. 31, 2022		55,429,046
Net income	49,861				49,861
Issuance of common stock for debt conversion	(3)		(3)
Issuance of common stock for debt conversion (in shares)		4
Exercise of stock options and vesting of stock units	166	$ 1	166
Exercise of stock options and vesting of stock units (in shares)		51,737
Tax withholding on vesting of restricted stock units	(2,448)		(2,448)
Tax withholding on vesting of restricted stock units (in shares)		(14,869)
Stock-based compensation expense	6,985		6,985
Translation adjustment	(15,517)			(15,517)
Other	(82)		(82)
Balance at Jun. 30, 2022	1,805,364	$ 555	1,533,762	(37,091)	308,138
Balance (Accounting Standards Update 2020-06 [Member]) at Jun. 30, 2022	(21,817)		(39,070)		17,253
Ending Balance, (in shares) at Jun. 30, 2022		55,465,918
Balance at Dec. 31, 2022	1,910,700	$ 556	1,547,266	(34,394)	397,272
Beginning Balance (in shares) at Dec. 31, 2022		55,557,698
Net income	35,123				35,123
Issuance of common stock for debt conversion	(3)	$ 0	(3)
Issuance of common stock for debt conversion (in shares)		6
Exercise of stock options and vesting of stock units	62	$ 2	60
Exercise of stock options and vesting of stock units (in shares)		176,394
Tax withholding on vesting of restricted stock units	(11,140)	$ (1)	(11,139)
Tax withholding on vesting of restricted stock units (in shares)		(63,238)
Issuance of common stock pursuant to the acquisition						$ 5,243		$ 5,243
Issuance of common stock pursuant to the acquisition, (in shares)							31,415
Issuance of common stock pursuant to contingent consideration earnout payment	7,229		7,229
Issuance of common stock pursuant to contingent consideration earnout payments		42,621
Stock-based compensation expense	12,737		12,737
Translation adjustment	(3,092)			(3,092)
Balance at Jun. 30, 2023	1,956,859	$ 557	1,561,393	(37,486)	432,395
Ending Balance, (in shares) at Jun. 30, 2023		55,744,896
Balance at Mar. 31, 2023	1,926,714	$ 556	1,544,956	(31,407)	412,609
Beginning Balance (in shares) at Mar. 31, 2023		55,644,301
Net income	19,786				19,786
Issuance of common stock for debt conversion	(3)		(3)
Issuance of common stock for debt conversion (in shares)		6
Exercise of stock options and vesting of stock units	33	$ 1	32
Exercise of stock options and vesting of stock units (in shares)		36,184
Tax withholding on vesting of restricted stock units	(1,547)		(1,547)
Tax withholding on vesting of restricted stock units (in shares)		(9,631)
Issuance of common stock pursuant to the acquisition						$ 5,243		$ 5,243
Issuance of common stock pursuant to the acquisition, (in shares)							31,415
Issuance of common stock pursuant to contingent consideration earnout payment	7,229		7,229
Issuance of common stock pursuant to contingent consideration earnout payments		42,621
Stock-based compensation expense	5,483		5,483
Translation adjustment	(6,079)			(6,079)
Balance at Jun. 30, 2023	$ 1,956,859	$ 557	$ 1,561,393	$ (37,486)	$ 432,395
Ending Balance, (in shares) at Jun. 30, 2023		55,744,896